Drug Profile


Alternative Names: PLX-4032; R-7204; RG-7204; RO-5185426

Latest Information Update: 17 Feb 2017

Price : $50

At a glance

  • Originator Plexxikon
  • Developer Chugai Pharmaceutical; Genentech; H. Lee Moffitt Cancer Center and Research Institute; Memorial Sloan-Kettering Cancer Center; Plexxikon; Roche; University Hospital Tubingen
  • Class 2 ring heterocyclic compounds; Antineoplastics; Chlorobenzenes; Fluorobenzenes; Pyridines; Pyrroles; Small molecules; Sulfonamides
  • Mechanism of Action Proto oncogene protein b raf inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant melanoma
  • Phase II Brain metastases; Colorectal cancer; Haematological malignancies; Multiple myeloma; Solid tumours; Thyroid cancer

Most Recent Events

  • 11 Jan 2017 Genentech collaborates with NCI Formulary to co-develop vemurafenib in Cancer
  • 23 Dec 2016 Chugai in collaboration with National Cancer Center completes a phase I trial of an expanded access programme in Malignant melanoma (Unresectable, Recurrent, BRAFV 600 mutation-positive) in Japan before December 2016 (UMIN000015572)
  • 03 Dec 2016 Efficacy and adverse events data from the VE-Basket phase II trial in Multiple myeloma presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top